EXTENDED REPORT

Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness

B A Biggee¹, C M Blinn², T E McAlindon¹, M Nuite¹, J E Silbert²

¹ Division of Rheumatology, Tufts New England Medical Centre, Boston, USA
² Connective Tissue Research Laboratory, Edith Nourse Rogers Memorial Veterans Hospital and Harvard Medical School, Brigham and Women’s Hospital, Division of Rheumatology/Immunology/Allergy, Bedford, USA

Correspondence to:
Dr J E Silbert
Edith Nourse Rogers Memorial Veterans Hospital, 200 Springs Road, Bedford, MA 01730, USA; jesilbert{at}aol.com

Background: Oral glucosamine preparations are widely used as a treatment for osteoarthritis, purportedly functioning by a variety of mechanisms suggested by results of in vitro experiments, and generally using glucosamine concentrations well in excess of 100 µmol/l.

Objective: To use high performance liquid chromatography with a high sensitivity Metrohm-Peak instrument for pulsed amperometric measurement of human serum glucosamine; a detection limit of 0.5 µmol/l at 1:10 serum dilution allowed measurement of low levels of glucosamine in human serum, which previously has not been possible.

Methods: Eighteen subjects with osteoarthritis were given 1500 mg of commercial glucosamine sulphate after an overnight fast, and serum was then obtained at baseline and every 15–30 minutes over 3 hours, and additionally, from two subjects at 5 and 8 hours. Urine samples were collected at baseline and 3 hours after ingestion from three subjects.

Results: Baseline glucosamine was below the detection limit of 0.5 µmol/l for all subjects, but after ingestion, glucosamine was detected in 17/18 subjects, beginning to rise at 30–45 minutes to a maximum at 90–180 minutes, with a range of 1.9–11.5 µmol/l (0.34–2 µg/ml).

Conclusion: This maximum concentration of 11.5 µmol/l has previously been shown to contribute less than 2% of the galactosamine incorporated into chondroitin sulphate in incubations of glucosamine with cultured human chondrocytes, and is a much lower concentration than the glucosamine concentrations claimed by other investigators to have various significant in vitro effects. This raises questions about current biological rationales for glucosamine use that were based on in vitro effects of glucosamine at much higher concentrations.

Abbreviations: BMI, body mass index; HPLC, high performance liquid chromatography; IL, interleukin

Keywords: osteoarthritis; glucosamine; human; serum; cartilage

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Silbert, J. E (2009). Dietary glucosamine under question. Glycobiology 19: 564-567 [Abstract] [Full Text]  
• Biggee, B. A, Blinn, C. M, Nuite, M., McAlindon, T. E, Silbert, J. E (2007). Changes in serum levels of glucosamine and sulphate after ingestion of glucosamine sulphate with and without simultaneous ingestion of glucose. Ann Rheum Dis 66: 1403-1404 [Full Text]  
• Katz, W. A. (2007). Themed Review: Nonpharmacologic Approaches to Osteoarthritis. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 1: 249-255 [Abstract]  
• Fulop, N., Zhang, Z., Marchase, R. B., Chatham, J. C. (2007). Glucosamine cardioprotection in perfused rat hearts associated with increased O-linked N-acetylglucosamine protein modification and altered p38 activation. Am. J. Physiol. Heart Circ. Physiol. 292: H2227-H2236 [Abstract] [Full Text]  
• Biggee, B A, Blinn, C M, Nuite, M, Silbert, J E, McAlindon, T E (2007). Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann Rheum Dis 66: 260-262 [Abstract] [Full Text]  
• Buckland-Wright, J. C., Messent, E. A., Bingham, C. O. III, Ward, R. J., Tonkin, C. (2007). A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 46: 257-264 [Abstract] [Full Text]  
• Muniyappa, R., Karne, R. J., Hall, G., Crandon, S. K., Bronstein, J. A., Ver, M. R., Hortin, G. L., Quon, M. J. (2006). Oral Glucosamine for 6 Weeks at Standard Doses Does Not Cause or Worsen Insulin Resistance or Endothelial Dysfunction in Lean or Obese Subjects. Diabetes 55: 3142-3150 [Abstract] [Full Text]  
• Tannock, L. R., Kirk, E. A., King, V. L., LeBoeuf, R., Wight, T. N., Chait, A. (2006). Glucosamine Supplementation Accelerates Early but Not Late Atherosclerosis in LDL Receptor-Deficient Mice. J. Nutr. 136: 2856-2861 [Abstract] [Full Text]